Literature DB >> 12921957

Effects of lower dose of imatinib to CML patients.

Akira Horikoshi, Kazuhiro Takei, Shigemasa Sawada.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12921957     DOI： 10.1016/s0145-2126(03)00101-2

Source DB:  PubMed          Journal:  Leuk Res        ISSN： 0145-2126            Impact factor:   3.156


× No keyword cloud information.
  6 in total

1.  Imatinib plasma trough concentration and its correlation with characteristics and response in Chinese CML patients.

Authors:  Qiu-bai Li; Chao Chen; Zhi-chao Chen; Hong-xiang Wang; Yan-lin Wu; Yong You; Ping Zou
Journal:  Acta Pharmacol Sin       Date:  2010-07-19       Impact factor: 6.150

2.  Imatinib for newly diagnosed chronic-phase chronic myeloid leukemia: results of a prospective study in Japan.

Authors:  Tadashi Nagai; Jin Takeuchi; Nobuaki Dobashi; Yuzuru Kanakura; Shuichi Taniguchi; Koji Ezaki; Chiaki Nakaseko; Akira Hiraoka; Masaya Okada; Yasushi Miyazaki; Toshiko Motoji; Masaaki Higashihara; Norifumi Tsukamoto; Hitoshi Kiyoi; Shinji Nakao; Katsuji Shinagawa; Ryuzo Ohno; Tomoki Naoe; Kazunori Ohnishi; Noriko Usui
Journal:  Int J Hematol       Date:  2010-06-25       Impact factor: 2.490

3.  Late response to low-dose imatinib in patients with chronic phase chronic myeloid leukemia.

Authors:  Akiyoshi Takami; Shigeki Ohtake; Eriko Morishita; Yasushi Terasaki; Toshihiro Fukushima; Toshiro Kurokawa; Naomi Sugimori; Sadaya Matano; Kinya Ohata; Chizuru Saito; Masaki Yamaguchi; Kohei Hosokawa; Hirohito Yamazaki; Yukio Kondo; Shinji Nakao
Journal:  Int J Hematol       Date:  2012-08-15       Impact factor: 2.490

Review 4.  Clinical profile of dasatinib in Asian and non-Asian patients with chronic myeloid leukemia.

Authors:  Dong-Wook Kim; Yeow-Tee Goh; Hui-Hua Hsiao; Priscilla B Caguioa; Dongho Kim; Wan-Seok Kim; Tapan Saikia; Shruti Agrawal; Amit Roy; David Dai; M Brigid Bradley-Garelik; Jaydip Mukhopadhyay; Saengsuree Jootar
Journal:  Int J Hematol       Date:  2009-05-20       Impact factor: 2.490

5.  Relationship between an effective dose of imatinib, body surface area, and trough drug levels in patients with chronic myeloid leukemia.

Authors:  Tatsuya Kawaguchi; Akinobu Hamada; Chie Hirayama; Reiko Nakashima; Takeru Nambu; Yuji Yamakawa; Hiroshi Watanabe; Kentaro Horikawa; Hiroaki Mitsuya; Hideyuki Saito
Journal:  Int J Hematol       Date:  2009-04-25       Impact factor: 2.490

6.  Efficacy and safety of dasatinib versus imatinib in the East Asian subpopulation of the DASISION trial of newly diagnosed chronic myeloid leukemia in chronic phase.

Authors:  Charles T Chuah; Hirohisa Nakamae; Zhixiang X Shen; M Brigid Bradley-Garelik; Dong-Wook Kim
Journal:  Leuk Lymphoma       Date:  2014-03-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.